Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Completed
Geron Corporation
Phase 1
2005-07-01
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in
treating patients with refractory or relapsed chronic lymphoproliferative disease.
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Completed
Geron Corporation
Phase 2
2010-11-01
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat
+ paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab)
alone for patients with locally recurrent or metastatic breast cancer who have not received
chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Completed
Breast Cancer Research Foundation
Phase 1
2011-01-01
A study to evaluate safety and biologic effects of giving GRN163L in combination with
trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to
therapy with trastuzumab.
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Completed
Geron Corporation
Phase 1
2011-01-01
A study to evaluate safety and biologic effects of giving GRN163L in combination with
trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to
therapy with trastuzumab.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
